Germany supply disruption unresolved
Third-party supplier disruption continues with no clear timeline for resolution; alternative supplier may take 3-4 quarters.
TORRENTPHARMACEUTICALS / Q3-FY26 / risks
Keep the risk register visible.
Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
JB Pharma integration disruption in Q4
Management expects Q4 to be muted due to change of control and process integration, potentially impacting sales.
GLP-1 launch delays in Brazil
Semaglutide launch delayed to next financial year; regulatory approval timeline uncertain despite prioritization.
US growth dependent on launch timing and competition
US revenue growth is contingent on timely new launches and competitive landscape, which are unpredictable.